Furthermore, the effect of SGLT2 inhibitors on cervical cancer development exhibited a significant difference when compared with the sulfonylurea group (aHR, 0.69; 95% CI, 0.50-0.94; Table 4). This evidence concerns the gene SLC5A2 and cervical cancer.